Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $63.45M
• Dividend Yield: N/A
• Average Volume (3M): 883.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -43.88%
• EPS Growth: 4.73%
• Country: US
• Employees: 202
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 37,546,436
• 10 Day Avg. Volume: 1,405,864
• 30 Day Avg. Volume: 883,524
• PEG Ratio: -0.12
• Price to Book (P/B): 0.58
• Price to Sales (P/S): 2.58
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: -1.69
• Enterprise Value/Revenue: -3.46
• Enterprise Value/Gross Profit: -15.11
• Enterprise Value/Ebitda: 1.27
• 1Y Price Target: $8.67
• Price Target Upside: 413.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $2.00 ▲(18.34% Upside)

The score is primarily weighed down by weak financial performance, including significant ongoing losses, high cash burn, and a notable revenue decline. Technicals are mixed with neutral momentum but a weaker trend versus longer moving averages, while valuation support is limited due to unprofitability. Offsetting factors include positive corporate developments around MGX-001 progress and actions aimed at extending the cash runway.

Positive Factors

Strategic Partnerships

The partnership with Acuitas allows Metagenomi to leverage advanced lipid nanoparticle technology, enhancing its gene-editing capabilities and expanding market reach.

Product Development

The promising preclinical results for MGX-001 highlight Metagenomi's potential to develop effective therapies, strengthening its product pipeline and market position.

Leadership Change

The appointment of a new CEO with strategic focus aims to enhance operational efficiency and drive the company towards its long-term goals.

Negative Factors

Profitability Challenges

Persistent profitability issues suggest high operational costs, which could hinder financial sustainability and require strategic cost management.

Cash Flow Concerns

Ongoing negative cash flows indicate potential liquidity challenges, necessitating careful cash management to ensure operational continuity.

Revenue Growth Volatility

Significant volatility in revenue growth may reflect market uncertainties or operational inefficiencies, impacting long-term growth prospects.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

How the Company Makes Money

Metagenomi generates revenue through multiple streams, primarily by partnering with pharmaceutical and biotechnology companies to develop and commercialize gene therapies. The company engages in strategic collaborations, licensing agreements, and research partnerships, which provide upfront payments, milestone payments, and royalties on sales of therapeutic products developed using its technology. Additionally, Metagenomi may receive funding from government grants and private investments aimed at advancing its research and development initiatives. Significant partnerships with established firms in the biotech space enhance its revenue potential by expanding its access to markets and resources.

Metagenomi, Inc. Financial Statement Overview

Summary

Metagenomi, Inc. shows strong revenue growth but faces significant profitability and cash flow challenges. The balance sheet is improving with positive equity, but liquidity and operational efficiency need attention.

Income Statement

Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.

Balance Sheet

The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.

Cash Flow

Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.91M	52.30M	44.76M	17.20M	243.00K
Gross Profit	7.08M	52.30M	-49.65M	15.47M	-144.00K
EBITDA	-84.58M	-83.49M	-74.28M	-39.19M	-20.75M
Net Income	-88.74M	-78.06M	-68.25M	-43.59M	-21.44M
Balance Sheet
Total Assets	247.94M	324.60M	364.84M	414.49M	141.99M
Cash, Cash Equivalents and Short-Term Investments	184.11M	248.31M	271.18M	362.13M	108.15M
Total Debt	41.66M	45.78M	48.23M	18.57M	48.93M
Total Liabilities	69.49M	89.74M	149.67M	488.91M	174.54M
Stockholders Equity	178.45M	234.86M	215.17M	-74.43M	-32.54M
Cash Flow
Free Cash Flow	-92.44M	-112.19M	-101.22M	15.75M	21.35M
Operating Cash Flow	-91.62M	-109.07M	-91.41M	29.72M	24.26M
Investing Cash Flow	99.71M	-88.16M	45.73M	-122.20M	-74.32M
Financing Cash Flow	-430.00K	84.01M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.69
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Negative. The current price of 1.69 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.75, and below the 200-day MA of 1.92, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.11 is Neutral, neither overbought nor oversold. The STOCH value of 25.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	62 Neutral	$146.87M	3.67	24.38%	―	―	814.20%
CNTX	56 Neutral	$139.66M	―	-33.68%	―	―	69.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MGX	49 Neutral	$63.45M	-0.70	-40.87%	―	-43.88%	4.73%
ATRA	46 Neutral	$33.31M	2.07	―	―	51.27%	―
IMUX	44 Neutral	$76.85M	-0.71	-398.50%	―	―	30.16%
HOWL	44 Neutral	$26.74M	-0.34	-122.43%	―	-100.00%	-8.30%

Metagenomi, Inc. Corporate Events

Metagenomi Therapeutics Rebrands to Emphasize Therapeutic Focus

On January 12, 2026, Metagenomi Therapeutics, Inc. formally changed its corporate name from Metagenomi, Inc. and updated its charter and bylaws accordingly, while retaining its Nasdaq listing under the ticker MGX and its existing CUSIP, signaling a strategic emphasis on its therapeutic focus rather than any change to shareholder rights or capital structure. In a related January 12, 2025 announcement, the company highlighted 2025 preclinical milestones for MGX-001, including curative and durable FVIII activity with no identifiable off-target editing in non-human primates and a completed pre-IND meeting in the fourth quarter of 2025, as well as progress in secreted protein deficiency and cardiometabolic programs, all under a pipeline reprioritization and revised capital allocation plan that extends its projected cash runway through the fourth quarter of 2027 and positions it for potential regulatory submissions in late 2026 and a first-in-human study of MGX-001 in 2027.

The most recent analyst rating on (MGX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Metagenomi Announces Positive Preclinical Data for MGX-001

On November 11, 2025, Metagenomi, Inc. announced positive preclinical data from its MGX-001 hemophilia A program, demonstrating curative FVIII activity in non-human primates. The company is prioritizing its MGX-001 program and other advanced therapeutics while reducing its workforce by 25% to extend its cash runway into the fourth quarter of 2027. Jian Irish has been appointed as the new CEO, succeeding Brian Thomas, who remains on the Board. This strategic shift is expected to enhance Metagenomi’s focus on its most promising programs and maintain financial discipline.

The most recent analyst rating on (MGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.